High Expression of USP22 Predicts Poor Prognosis and Advanced Clinicopathological Features in Solid Tumors: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jun 7

PMID 29872315

Citations 14

Authors

Xiaohui Yang

Haiyang Zang

Yingbin Luo

Jianchun Wu

Zhihong Fang

Weikang Zhu

Yan Li

Affiliations

Soon will be listed here.

Abstract

Introduction: The expression of USP22 has been demonstrated to play a pivotal role in solid tumors. However, the prognostic value of USP22 still remains unknown.

Materials And Methods: A systematic meta-analysis was performed to assess the prognostic value of USP22 in cancers. A literature collection was conducted from inception to June 8, 2017 by searching PubMed, Cochrane Library, Embase, Ovid and Web of Science databases. The pooled hazard ratio (HR) and odds ratio (OR) were used to correlate high expression of USP22 with overall survival (OS) and clinicopathological features.

Results: The results, pooled by 19 studies with 2,876 cases, indicated that high expression of USP22 predicted poor OS (HR=2.48, 95% CI: 2.11-2.84, <0.001) and disease-free survival (DFS; HR=2.55, 95% CI: 2.05-3.05, <0.001) of cancer patients. Furthermore, high expression of USP22 was also significantly associated with advanced clinicopathological parameters, including tumor stage, tumor differentiation, metastasis, nodal status and tumor size.

Conclusion: Our finding revealed that USP22 might be an indicator of poor prognosis and advanced clinicopathological features of solid tumors and could be served as a novel biomarker.

Citing Articles

Clinicopathological and Prognostic Value of USP22 Expression in Gastric Cancer: A Systematic Review and Meta-Analysis and Database Validation.

Wang Y, Jia Z, Gao J, Zhou T, Zhang X, Zu G Front Surg. 2022; 9:920595.

PMID: 35784926 PMC: 9243499. DOI: 10.3389/fsurg.2022.920595.

M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression.

Yadav P, Subbarayalu P, Medina D, Nirzhor S, Timilsina S, Rajamanickam S Cancer Res. 2022; 82(10):1872-1889.

PMID: 35303054 PMC: 9336196. DOI: 10.1158/0008-5472.CAN-21-2106.

The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22.

Stanek T, Gennaro V, Tracewell M, Di Marcantonio D, Pauley K, Butt S EMBO J. 2021; 40(16):e102509.

PMID: 34155658 PMC: 8365265. DOI: 10.15252/embj.2019102509.

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.

Fhu C, Ali A Cancers (Basel). 2021; 13(7).

PMID: 33805973 PMC: 8037609. DOI: 10.3390/cancers13071513.

USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization.

Wei Y, Jiang Z, Lu J Oncol Lett. 2021; 21(5):394.

PMID: 33777217 PMC: 7988733. DOI: 10.3892/ol.2021.12655.

References

Allemani C, Weir H, Carreira H, Harewood R, Spika D, Wang X . Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2014; 385(9972):977-1010. PMC: 4588097. DOI: 10.1016/S0140-6736(14)62038-9. View

Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M . Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001; 15(16):2042-7. PMC: 312761. DOI: 10.1101/gad.907901. View

Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S . High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2015; 6(14):12654-67. PMC: 4494964. DOI: 10.18632/oncotarget.3705. View

Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H . USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 2015; 88(3):239-45. DOI: 10.1016/j.lungcan.2015.02.019. View

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Kim D, Hong A, Park H, Shin W, Yoo L, Jeon S . Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J Cell Physiol. 2017; 232(12):3664-3676. DOI: 10.1002/jcp.25841. View

Chipumuro E, Henriksen M . The ubiquitin hydrolase USP22 contributes to 3'-end processing of JAK-STAT-inducible genes. FASEB J. 2011; 26(2):842-54. DOI: 10.1096/fj.11-189498. View

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

Wang H, Li Y, Chen J, Yuan S, Wang L, Zhang J . Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biol. 2013; 34(3):1635-9. DOI: 10.1007/s13277-013-0696-0. View

10.

Love K, Catic A, Schlieker C, Ploegh H . Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol. 2007; 3(11):697-705. DOI: 10.1038/nchembio.2007.43. View

11.

Karapanagiotou E, Terpos E, Dilana K, Alamara C, Gkiozos I, Polyzos A . Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol. 2009; 27(2):332-8. DOI: 10.1007/s12032-009-9214-z. View

12.

Li J, Wang Z, Li Y . USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2012; 138(8):1291-7. DOI: 10.1007/s00432-012-1191-5. View

13.

Atanassov B, Dent S . USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011; 12(9):924-30. PMC: 3166460. DOI: 10.1038/embor.2011.140. View

14.

Le Q, Chen E, Salim A, Cao H, Kong C, Whyte R . An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; 12(5):1507-14. DOI: 10.1158/1078-0432.CCR-05-2049. View

15.

Ning Z, Wang A, Liang J, Xie Y, Liu J, Feng L . USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma. Int J Oncol. 2014; 45(4):1594-608. DOI: 10.3892/ijo.2014.2531. View

16.

Berger S . The complex language of chromatin regulation during transcription. Nature. 2007; 447(7143):407-12. DOI: 10.1038/nature05915. View

17.

Lv L, Xiao X, Gu Z, Zeng F, Huang L, Jiang G . Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 2010; 346(1-2):11-21. DOI: 10.1007/s11010-010-0585-4. View

18.

Ning J, Zhang J, Liu W, Lang Y, Xue Y, Xu S . Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 2013; 56(4):e46. PMC: 3567765. DOI: 10.4081/ejh.2012.e46. View

19.

Zhang X, Varthi M, Sykes S, Phillips C, Warzecha C, Zhu W . The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008; 29(1):102-11. PMC: 2254522. DOI: 10.1016/j.molcel.2007.12.015. View

20.

Zhao H, Tang H, Liu N, Zhao Y, Liu Q, Zhu X . Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma. Oncotarget. 2016; 7(21):31191-203. PMC: 5058749. DOI: 10.18632/oncotarget.9098. View